Form 4: Aerovate Therapeutics Director, David S. Grayzel, Reports Stock Option Grant

Director David S. Grayzel reports the acquisition of stock options in Aerovate Therapeutics, with vesting conditions tied to continued service and the next annual meeting.

Summary

• David S. Grayzel, a director of Aerovate Therapeutics, Inc., reported the grant of a stock option on June 5, 2024.
• The option allows him to purchase 12,500 shares of common stock at an exercise price of $18.90 per share.
• The options vest fully on the earlier of June 5, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service.
• The director disclaims ownership of the securities, as proceeds from any sale will be transferred to Atlas Venture Life Science Advisors, LLC, except for any pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant, which is generally neutral. The disclaimer of ownership adds a slight negative nuance.

Positives

• The grant of stock options to a director aligns their interests with the company's success.
• The vesting schedule incentivizes continued service and commitment to Aerovate Therapeutics.

Risks

• The director disclaims ownership of the securities, which may reduce the direct alignment of personal financial interest with company performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies an expectation of continued service from the director.

Management Comments

• The Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded biotech companies.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• The exercise price is set at $18.90, which may be compared to the market price of AVTE shares at the time of the grant to assess its competitiveness.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The grant incentivizes the director to contribute to the company's success, which benefits shareholders.

Key Dates